Archive for the ‘Int J Clin Exp Med’ Category
Sometimes we come across a real head-scratcher.
That happened this week, when we saw a retraction notice for a 2015 paper on gastric cancer in the International Journal of Clinical and Experimental Medicine, which only says the authors “made big mistakes” and contains two fairly significant typos.
Although there’s no sign of a retraction on PubMed, the table of contents for the latest issue of the journal lists the retraction — but includes no hyperlink to the notice. The only way to see it is via a Web cached version. Here’s the text:
Sometime in the middle of 2015, Jennifer Byrne, professor of molecular oncology at the University of Sydney, began her journey from cancer researcher to a scientific literature sleuth, seeking out potentially problematic papers.
The first step was when she noticed several papers that contained a mistake in a DNA construct which, she believed, meant the papers were not testing the gene in question, associated with multiple cancer types. She started a writing campaign to the journal editors and researchers, with mixed success. But less than two years later, two of the five papers she flagged have already been retracted.
When asked why she spent time away from bench research to examine this issue, Byrne told us: Read the rest of this entry »
The authors of a paper about the benefits of an antioxidant found in blueberries known as pterostilbene have retracted it after their subsequent research suggested the antioxidant might actually be harmful.
found that pterostilbene might induce apoptosis in the heart and can be harmful, and we are now focusing on the phenomenon.
The rest of the retraction note for “Pterostilbene attenuates inflammation in rat heart subjected to ischemia-reperfusion: role of TLR4/NF-κB signaling pathway,” published in the International Journal of Clinical and Experimental Medicine, suggests that the authors would consider republishing their findings if they became more confident in the data: